Stay updated with breaking news from David Grayzel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Financing was led by New Enterprise Associates (NEA) and closed with additional new investor Atlas Venture and continued investment by GV and F-Prime CapitalSignificant investment by top-tier syndicate endorses Comanche’s
Frank William ("Bill") Dickinson, 82, died on June 5 after a long illness. Bill was a vivacious person who led a life full of love, travel and...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Published: Dec 22, 2020 CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of industry leader Mark Iwicki as Chairman of its Board of Directors. Mr. Iwicki will succeed Dr. David Grayzel as Chairman. Dr. Grayzel, an Atlas Venture partner and co-founder of Q32, will continue as a Director. Mr. Iwicki has over 25 years of biopharmaceutical leadership experience managing all stages of drug development and commercialization across multiple therapeutic areas. Mr. Iwicki...